血小板输注量对动脉-静脉体外膜肺氧合患者预后的影响：一项连续三年的回顾性研究

目的:研究血制品在动脉-静脉体外膜肺氧合（veno-arterial extracorporeal membrane oxygenation,VA-ECMO）患者中的应用并探讨其对预后的影响。方法:回顾性分析2017年1月至2020年6月于南京医科大学第一附属民医院急诊科行VA-ECMO治疗的成人患者共83例。分析死亡组（ n=37）和存活组（ n=46）患者的基线资料差异，并采用二元logistic回归分析VA-ECMO患者28 d病死率的相关危险因素，并采用ROC曲线计算阈值。 结果:：血小板输注量（ OR=2.506，95% CI：1.142~5.499， P=0.022）、非心肌炎性疾病（ OR=6.881，95% CI：1.615~29.316， P=0.009）为成人VA-ECMO患者28 d病死率的相关危险因素，血小板输注量阈值为0.427 mL/(kg·d)，可预测患者ECMO上机28 d病死率，敏感度为78.4%，特异性为69.6%（曲线下面积：0.735）。 结论:血小板输注量的增加与成人VA-ECMO患者的不良预后相关，心肌炎患者行VA-ECMO治疗效果较好。

Platelet transfusion practice and related outcomes in patients with veno-arterial extracorporeal membrane oxygenation: a three-year retrospective study

Objective:To study the application of blood products in patients with veno-arterial extracorporeal membrane oxygenation (VA-ECMO) and evaluate its effect on the prognosis.Methods:A total of 83 adult patients treated with VA-ECMO in the Emergency Department of the First Affiliated Hospital of Nanjing Medical University from January 2017 to January 2020 were grouped by survival to explore the risk factors of 28-day mortality using binary logistic regression, and the threshold was calculated by ROC curve.Results:Platelet transfusion ( OR=2.506, 95% CI: 1.142-5.499) and non-myocarditis disease ( OR=6.881, 95% CI: 1.615-29.316) were the risk factors of 28-day mortality in adult VA-ECMO patients. The threshold of platelet transfusion was 0.427 mL/(kg·d) (sensitivity 78.4%, specificity 69.6% , AUC 0.735). Conclusions:The increased platelet transfusion is related to the poor prognosis of adult patients with VA-ECMO. Refractory myocarditis patients are better treated with VA-ECMO.